
CLAIMS

1. Use of a pharmaceutical composition, comprising a compound represented by a following chemical Formula 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates thereof, solvates thereof, or mixtures thereof; and at least one selected from evogliptin, sitagliptin, elafibranor, dapagliflozin, metformin and voglibose, in the manufacture of a medicament for preventing or treating diabetes or at least one disease of obesity and dyslipidemia:

[Formula 1]





wherein in above Formula 1,

A is an oxadiazole group, in which above A is substituted with a C1-C6 straight or branched chain alkyl group;

B is a pyrimidine group, in which above B is substituted with a C1-C6 straight or branched chain alkyl group; and


X is F.

2. The use of a pharmaceutical composition according to claim 1, wherein above

A is  or  , and

R_2 and R_3 are each independently a C1-C6 straight or branched chain alkyl group.

3. The use of a pharmaceutical composition according to claim 1, wherein above

B is  , and

R_7 is a C1-C6 straight or branched chain alkyl group.

4. The use of a pharmaceutical composition according to claim 1, wherein the compound represented by above Formula 1 is 3-(4-(3-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)propoxy)-2,6-difluorophenyl)-5-isopropyl-1,2,4-oxadiazole.